Early tirofiban versus heparin for bridging dual antiplatelet therapy in patients undergoing coronary endarterectomy combined with coronary artery bypass grafting: a multicenter randomized controlled trial protocol (the THACE-CABG trial).

"Declarations Ethics approval and consent to participate {24}The THACE-CABG research project was approved by the institutional review boards of Beijing Anzhen Hospital, Beijing Tiantan Hospital, Peking University Shenzhen Hospital, and the First Affiliated Hospital of Harbin Medical University in August 2022 (Ethics Number: KS2022051). Informed consent will be obtained from all study participants. Consent for publication {32}Consents for publication will be available from the corresponding author on request. No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials are attached as supplementary materials. Competing interests {28}The authors declare no competing interests. Competing interests {28} The authors declare no competing interests."

"Funding {4} The THACE-CABG trial is supported by grants from the Capital Health Research and Development of Special Fund (No. 2020–1-2061), Beijing Hospitals Authority’s Ascent Plan (Code: DFL20220605), and Beijing Municipal Natural Science Foundation (No. 7214222)."

"Trial registration chictr.org.cn, ChiCTR2200055697. Registered 6 January 2022. https://www.chictr.org.cn/com/25/showproj.aspx?proj=149451. Current version: 20,220,620."